H. R. 3023 was recently introduced in Congress by the chairmen of the House Ways and Means Committee and the House Energy and Commerce Committee to require disclosure of gifts, provided directly or indirectly, with a value in excess of $50 in the aggregate for each annual reporting period, by any drug or medical device manufacturer, packer or distributor or their agents to any doctor, nurse, therapist, hospital, nursing home, pharmacist or any other person authorized to dispense drugs. In addition, H.R. 3023 requires similar reporting of any cash rebate, discount, or any other financial consideration provided to any pharmaceutical benefit manager. Gifts include any gifts, fees, payments, subsidy, amenity, objects, service or other economic benefit except for free samples intended for patients, scholarships or bona fide clinical trials. Since this legislation was introduced jointly by the chairmen of the Ways and Means Committee and the Energy and Commerce Committee, it is likely that the concept will be enacted, probably through attachment to other legislation.